Summary of Study ST001517

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench,, where it has been assigned Project ID PR000960. The data can be accessed directly via it's Project DOI: 10.21228/M8M39X This work is supported by NIH grant, U2C- DK119886.


Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)
Study IDST001517
Study TitleIdentification of distinct metabolic perturbations and associated immunomodulatory events during intra-erythrocytic development stage of pediatric Plasmodium falciparum malaria (part-III)
Study SummaryThe goal of this study was to interrogate biochemical profiles manifested in human serum samples originating from a cohort of West African children, collected before and during P. falciparum malarial infection, with the aim of characterizing metabolic migration associated with severity of malarial infection.
New York University Abu Dhabi
Last NameAbdrabou
First NameWael
AddressSaadiyat Island, P.O Box 129188, Abu Dhabi
Submit Date2020-08-25
Num Groups2
Total Subjects53
Num Males21
Num Females32
Analysis Type DetailLC-MS
Release Date2021-04-27
Release Version1
Wael Abdrabou Wael Abdrabou application/zip

Select appropriate tab below to view additional metadata details:


Subject ID:SU001591
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606
Age Or Age Range:5-12 years
Gender:Male and female
Human Ethnicity:Fulani (Burkina Faso, West Africa)
Human Inclusion Criteria:residency in the Sapone district area in Burkina Faso, age of 5 to 12 years, no P. falciparum infection at the time of enrollment (as evidenced by malaria rapid diagnostic test and confirmed later with microscopy and qPCR), no fever (axillary temperature ≥37.5°C) or history of fever within the preceding 48 hours
Human Exclusion Criteria:history of immunosuppressive diseases or chronic diseases, signs of concomitant febrile illness or active infection, use of anti-malarial treatment within the preceding two weeks, use of immunosuppressant or other immune-modifying drugs within the preceding six months and receiving blood transfusion within the preceding three months